BFLY vs PACB

Key Takeaways

• Butterfly Network has delivered a remarkable one-year return above 280%, driven by a landmark partnership with Midjourney and accelerating revenue growth, while Pacific Biosciences has declined roughly 9% over the same period amid a major restructuring.
• Both companies operate in healthcare technology but occupy fundamentally different segments: BFLY is a digital ultrasound platform company, while PACB is a long-read DNA sequencing provider.
• BFLY recently achieved its first quarter of positive operating cash flow and guided for 20–24% revenue growth in 2026; PACB is targeting cash flow breakeven by late 2027 after divesting its short-read sequencing assets.
• PACB holds a larger cash reserve of approximately $280 million versus BFLY's $155 million, though BFLY's cash burn rate has been shrinking faster.
• Analyst consensus rates BFLY as a "Strong Buy" with a price target near $7.06, while PACB holds a "Buy" rating with a price target of $2.46 — implying roughly 76% upside from current levels.
• Both stocks carry elevated beta values above 2.0, indicating higher-than-average volatility relative to the broader market.

Introduction

Healthcare technology remains one of the most dynamic sectors in the equity market, attracting investors who seek exposure to innovation-driven growth. BFLY and PACB represent two distinct approaches to transforming medical diagnostics — portable ultrasound imaging and long-read genomic sequencing, respectively. This comparison is particularly relevant for growth-oriented investors evaluating high-beta healthcare names that are not yet profitable but are pursuing large addressable markets. Understanding how these two companies differ in business model, momentum, risk profile, and market positioning can help traders make more informed assessments.

BFLY Overview and Recent Performance

BFLY — Butterfly Network, Inc. — is a digital health company that has pioneered semiconductor-based, handheld ultrasound technology. Its Ultrasound-on-Chip platform powers portable devices including the iQ+ and iQ3 probes, which connect to smartphones and tablets for whole-body imaging. The company has been expanding beyond hardware into enterprise software with its Compass AI platform and has built a cloud-based imaging ecosystem.

In recent months, BFLY's stock has experienced substantial upward momentum. Over the trailing twelve months, shares have surged more than 280%, lifting the company's market capitalization to approximately $1.86 billion. The most significant catalyst has been a co-development and licensing agreement with Midjourney, an independent AI research lab, signed in late 2025. The deal contributed $6.8 million to fourth-quarter 2025 revenue and is structured as a multi-year contract worth up to $74 million, with potential additional revenue from future chip sales and commercialization. BFLY reported full-year 2025 revenue of $97.6 million, up 19% year over year, and guided for 2026 revenue of $117–$121 million. The company also achieved a milestone of positive operating cash flow in Q4 2025 for the first time in its history, supported by upfront payments from the Midjourney contract. Gross margin reached 67% in the fourth quarter, and the company ended 2025 with $154.5 million in cash.

PACB Overview and Recent Performance

PACB — Pacific Biosciences of California, Inc. — is a life sciences company specializing in advanced DNA sequencing systems. Its core technology, called HiFi (high-fidelity) long-read sequencing, allows researchers to decode genetic information with greater accuracy and completeness than traditional short-read approaches. The company markets instruments such as the Revio and Vega sequencing platforms, along with consumable reagent kits and software services, primarily to academic laboratories, clinical researchers, and pharmaceutical developers.

PACB's stock has faced notable headwinds in recent market activity. Shares are trading near $1.40, reflecting a roughly 9% decline over the past year and a year-to-date decline of approximately 25%. The company underwent a significant restructuring in 2025, refocusing its business entirely on long-read sequencing and divesting its short-read sequencing assets for net proceeds of approximately $48.1 million. Full-year 2025 revenue reached $160 million, representing a modest increase from $154 million in 2024. Non-GAAP (Generally Accepted Accounting Principles adjusted) gross margin improved to 40% for the year, up from 33%. However, GAAP net loss widened to $546.4 million due largely to restructuring charges and impairment costs. On a non-GAAP basis, the net loss narrowed to $158.8 million from $228 million the prior year. The company ended 2025 with $279.5 million in cash and investments and is targeting cash flow breakeven by the end of 2027, driven partly by the upcoming launch of SPRQ-Nx chemistry, which is expected to meaningfully reduce sequencing costs per genome.

Trending AI Robots

For traders seeking an analytical edge in evaluating stocks like BFLY and PACB, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only the highest-conviction strategies aligned with current market conditions earn a place in the Trending AI Robots section. These bots span multiple trading styles and timeframes — from 5-minute and 15-minute intraday agents to 60-minute swing trading models — and have delivered annualized returns ranging from approximately 30% to over 190% across various strategies, with win rates reaching as high as 67–77% in select models. Each bot employs proprietary Financial Learning Models (FLMs) that continuously adapt to shifting market dynamics, and traders can review complete performance statistics, closed trade logs, and open positions. Explore the full lineup at Trending AI Robots to discover which strategies align with your investment approach.

Head-to-Head Comparison

When comparing BFLY and PACB, several contrasts stand out. In terms of business model maturity, BFLY is transitioning from a device-centric model to a platform company, leveraging its semiconductor chip to generate licensing revenue through the Butterfly Embedded initiative. PACB, by contrast, has streamlined its focus to long-read sequencing after exiting the short-read market, betting that instruments like Vega and chemistries like SPRQ-Nx will drive adoption in clinical and research settings.

On growth trajectory, BFLY currently exhibits stronger momentum. Its 41% year-over-year revenue growth in Q4 2025 and 20–24% guidance for 2026 outpace PACB's more modest mid-single-digit growth profile. BFLY's Midjourney deal provides a non-dilutive revenue stream that validates the platform strategy, whereas PACB's growth relies more heavily on instrument placements and consumable pull-through in a competitive genomics landscape.

Risk factors differ meaningfully between the two. BFLY faces tariff-related headwinds on hardware components and operates in a competitive medical device market. PACB contends with academic funding uncertainties — particularly around NIH (National Institutes of Health) budgets — and U.S.-China trade policy exposure that has pressured instrument exports. PACB also carries a high short interest (approximately 16% of float), which introduces potential for both sharp rallies and elevated downside risk.

From a valuation perspective, BFLY trades at a forward price-to-sales multiple above 15x based on 2026 guidance, while PACB trades at roughly 2.5x forward sales. This gap reflects the market's stronger conviction in BFLY's growth narrative, though it also means BFLY shares embed higher expectations. Both companies remain unprofitable on a GAAP basis, but BFLY's path toward operating cash flow positivity appears nearer than PACB's 2027 breakeven target.

Tickeron AI Verdict

Based on observable market data and trend consistency, Tickeron's AI analytical framework would likely express a relative preference for BFLY over PACB in the current environment. The reasoning centers on several probabilistic factors: BFLY's price trend has demonstrated significantly stronger directional momentum over the trailing twelve months, revenue growth is accelerating rather than stabilizing, and the Midjourney partnership provides a differentiated catalyst that extends beyond the company's core handheld ultrasound market. BFLY's achievement of positive operating cash flow in the most recent quarter also signals improving financial discipline. Meanwhile, PACB's restructuring-driven transition, while potentially value-creating over the longer term, introduces near-term execution uncertainty and has not yet translated into sustained positive price momentum. Both stocks carry elevated volatility risk, and no outcome is certain, but the weight of observable evidence currently tilts in BFLY's favor.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations